Tectonic Therapeutic, Inc. (TECX)

NGM – Real Time Price. Currency in USD

31.99

+0.96 (3.09%)

At close: Jun 26, 2026, 4:00 PM EDT

31.99

0.00 (0.00%)

After-hours: Jun 26, 2026, 4:55 PM EDT

10.06.2026

Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients

WATERTOWN, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic” or the “Company”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced the completion of enrollment for the APEX trial, a 24-week Phase 2 clinical trial evaluating the safety and efficacy of TX45 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (“PH-HFpEF”). The trial was designed to include an enriched population of a more severe disease subtype of combined pre- and post-capillary pulmonary hypertension (“CpcPH”) patients with a pulmonary vascular resistance (“PVR”)> 3 Wood Units (“WU”) at baseline.

07.05.2026

Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights

WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic” or the “Company”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced financial results for the first quarter ended March 31, 2026, and provided an overview of recent business highlights.

23.04.2026

Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors

WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed Jessica Chutter to its Board of Directors, effective June 8, 2026.

16.04.2026

Tectonic Therapeutic: A $1B+ Opportunity Hinges On Upcoming Phase 2

Tectonic Therapeutic is reviving relaxin biology with TX45, targeting Group 2 Pulmonary Hypertension with HFpEF, a large underserved market. TX45's engineered Fc-relaxin fusion overcomes prior failures by extending half-life, enabling durable hemodynamic improvements in the CpcPH subgroup per robust phase 1b data. With a $253.8M cash balance, TECX is funded for phase 2; positive topline data in 2026 could unlock a $0.6B–$1.8B U.S. peak sales opportunity.

06.03.2026

Tectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

26.02.2026

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided an overview of recent business highlights.

23.02.2026

Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board.

Videos

No Data

There is no data to display

Press releases

10.06.2026

Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients

07.05.2026

Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights

23.04.2026

Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors

26.02.2026

Tectonic Therapeutic, Inc. (TECX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Tectonic Therapeutic, Inc. (TECX)

Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients

Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights

Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors

Tectonic Therapeutic: A $1B+ Opportunity Hinges On Upcoming Phase 2

Tectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

Videos

No Data

Press releases

Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients

Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights

Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients

Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights

Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors

Tectonic Therapeutic: A $1B+ Opportunity Hinges On Upcoming Phase 2

Tectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

Videos

No Data

Press releases

Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients

Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights

Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Search stocks

Tectonic Therapeutic, Inc. (TECX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Tectonic Therapeutic, Inc. (TECX)

Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients

Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights

Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors

Tectonic Therapeutic: A $1B+ Opportunity Hinges On Upcoming Phase 2

Tectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

Videos

No Data

Press releases

Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients

Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights

Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients

Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights

Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors

Tectonic Therapeutic: A $1B+ Opportunity Hinges On Upcoming Phase 2

Tectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

Videos

No Data

Press releases

Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients

Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights

Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights